Loading...
Veru Inc. reported a 34% increase in net revenues and a 47% increase in gross profit for the fiscal 2021 second quarter, driven by record high quarterly FC2 US prescription net revenues.
Net revenues increased 34% to $13.3 million.
FC2 prescription net revenues climbed 48% to $10.3 million.
Gross profit rose 47% to $10.9 million.
Company poised to enroll first patient in Phase 3 VERACITY clinical trial of Sabizabulin for metastatic castration and AR targeting agent resistant prostate cancer later this month.
Analyze how earnings announcements historically affect stock price performance